Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Current Taxes (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Current Taxes for 8 consecutive years, with $302000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Taxes fell 83.73% to $302000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $302000.0, a 83.73% decrease, with the full-year FY2025 number at $302000.0, changed N/A from a year prior.
  • Current Taxes was $302000.0 for Q4 2025 at Outlook Therapeutics, roughly flat from $302000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $1.9 million in Q4 2024 to a low of $302000.0 in Q3 2025.